跳到正文
原文
Medical Xpress·· 16 天前AI 评分46

新药物开发策略可能通过清除抑制有益酶的蛋白质来保护神经元

New drug-development strategy might protect neurons by displacing proteins that inhibit helpful enzymes

AI 导读

研究人员发现了一种新的药物开发策略,通过激活酶来清除多种有害蛋白质,改善线粒体功能和神经元存活。该策略在实验室测试中保护了神经元免于过早死亡,类似于已批准药物的效果。

正文
New drug-development strategy might protect neurons by degrading proteins that inhibit helpful enzymes
Stimulated protein degradation restores mitochondrial function and neuronal survival. Credit: Science (2026). DOI: 10.1126/science.aed2525

Researchers from the University of California, Berkeley may have discovered a new strategy for treating complex neurodegenerative diseases. Their study, recently published in Science, describes a new approach that allows specialized enzymes to clear out several disease-causing proteins. So far, the method has proved useful for protecting neurons in lab tests.

Fighting disease-causing proteins

Mitochondria are crucial for supplying energy to cells, but misfolded and dysfunctional proteins can disrupt this process and block healthy proteins. This can ultimately lead to nerve and muscle degeneration and neurodegenerative diseases. Clearing out the bad proteins can help mitochondria import the proteins needed to assemble their energy-producing machinery.

One emerging therapeutic strategy, called targeted protein degradation (TPD), has been shown to eliminate disease-causing proteins. TPD works by destroying disease-causing proteins rather than just blocking their function and has the potential to treat cancer, autoimmune diseases and inflammatory syndromes. However, TPD typically only targets one type of protein at a time, while complex diseases can involve many disrupted proteins. This generally makes a single-protein target insufficient for a robust treatment approach.

An alternative to targeting single proteins

Previous studies had identified an enzyme called the E3 ligase CUL2FEM1B that clears away multiple harmful proteins obstructing entry channels into mitochondria. Other studies identified BEX proteins that act as brakes on this enzyme and showed that certain genetic changes could release that inhibition, allowing the E3 ligases to clear these channels and help mitochondria function efficiently again.

The team involved in the new study decided to search for a small molecule that might be able to activate this enzyme. They screened roughly 120,000 compounds for molecules that displace the BEX protein inhibiting the E3 ligase while preserving recognition of a natural target. They identified two molecules, referred to as BEX displacer 1 (BD1) and BEX displacer 2 (BD2), that could displace the BEX proteins and potentially free up the E3 enzymes.

The team conducted structural studies and genetic controls to establish how the compounds acted on the enzyme. They also did tests on engineered cells and human stem cell–derived neurons to measure protein breakdown, mitochondrial function and cell survival. Results showed that BD2 displaced all BEX proteins and ultimately increased the breakdown of several natural enzyme targets, improving healthy protein delivery into mitochondria and increasing mitochondrial respiration.

The study authors write, "These molecules trigger degradation of multiple physiological targets and elicit protective signaling with sufficient potency to overcome cellular phenotypes of neurodegenerative diseases. Because E3 ligase agonists accelerate turnover of native targets, rather than creating neosubstrates, we refer to this approach as stimulated protein degradation (SPD). Given the widespread regulation of E3 ligases by inhibitory proteins, we anticipate that SPD may provide a broadly applicable strategy that could benefit patients of many stress-related pathologies."

A step toward disease treatment

The researchers used cellular models to test if the method would work on diseases like COX deficiency syndrome, which is a rare genetic metabolic disorder, and Friedreich's ataxia, a rare, inherited neurodegenerative disorder that causes progressive damage to the nervous system and impairs muscle coordination and balance.

In the COX deficiency syndrome tests, BD2 restored respiratory function and protected lab-grown neurons from premature death. BD2 also protected neurons modeling Friedreich's ataxia. Its survival benefit was similar to that of the approved drug omaveloxolone in these laboratory tests, although this has not been tested on humans or animals directly.

Furthermore, the method restored function without producing any detectable oxidative stress or mitochondrial damage under the conditions tested. Still, further testing is needed to establish whether the compounds can safely reach affected tissues, including the brain. Additional work can determine if similar inhibitor-displacement strategies might activate other protective E3 ligases as well.

The study authors write, "These findings suggest that BD2 could serve as a starting point for treatments against several pathologies linked to compromised mitochondrial function."

A Perspective article on the research was also published in Science

Written for you by our author Krystal Kasal, edited by Gaby Clark, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

Srividya Chandrasekhar et al., Stimulated protein degradation to promote mitochondrial function and neuronal survival, Science (2026). DOI: 10.1126/science.aed2525

Ramanujan S. Hegde, Taking the brakes off a stress response, Science (2026). DOI: 10.1126/science.aem1560

Journal information: Science

Who's behind this story?

Krystal Kasal

Krystal Kasal

Freelance science writer with Master's in physics. Five years clinical research and physics education experience. Science communicator. Full profile →

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: New drug-development strategy might protect neurons by displacing proteins that inhibit helpful enzymes (2026, November 4) retrieved 4 November 2026 from https://medicalxpress.com/news/2026-11-drug-strategy-neurons-displacing-proteins.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com